Pharmacokinetics of 14C-ciclesonide after oral and intravenous administration in healthy subjects

R. Nave, T. D. Bethke, S. P. van Marle, K. Zech (Konstanz, Germany; Zuidlaren, The Netherlands)

Source: Annual Congress 2002 - Asthma and COPD: pharmacology
Session: Asthma and COPD: pharmacology
Session type: Thematic Poster Session
Number: 745
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Nave, T. D. Bethke, S. P. van Marle, K. Zech (Konstanz, Germany; Zuidlaren, The Netherlands). Pharmacokinetics of 14C-ciclesonide after oral and intravenous administration in healthy subjects. Eur Respir J 2002; 20: Suppl. 38, 745

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002

Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers
Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma
Year: 2012


Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers
Source: Eur Respir J 2006; 28: Suppl. 50, 332s
Year: 2006

Effect of oral guaifenesin (Mucinex 1200mg) on mucociliary clearance from the lungs of healthy non-smoking adults
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010


Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009


Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018




Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500μg to 1000μg are dose-linear in healthy subjects
Source: Eur Respir J 2002; 20: Suppl. 38, 108s
Year: 2002

Safety and tolerability of single doses of AZD5069 in healthy volunteers
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012


Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CSCR2, in healthy volunteers
Source: Annual Congress 2007 - New insights into the treatment of COPD
Year: 2007


Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Safety, pharmacokinetics, and pharmacodynamics of TD-8236, an inhaled pan-JAK inhibitor, following single- and multiple-ascending doses in healthy volunteers and mild asthmatics
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Year: 2021



The effect of fluconazole on the pharmacokinetics of ensifentrine in healthy individuals
Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies
Year: 2021


Excretion and metabolism of [14C]aclidinium bromide administered intravenously in healthy subjects
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010


Single-dose, first-in-human study of AMG 853: Pharmacokinetics, pharmacodynamics, and safety in healthy adults
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

Pharmacokinetics of consecutive oral moxifloxacin 400 mg/day in patients with respiratory tract infection
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010


Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500µg roflumilast in the morning versus evening
Source: Eur Respir J 2003; 22: Suppl. 45, 102s
Year: 2003

Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients
Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies
Year: 2009